Compounds > l 345
Page last updated: 2024-12-07

l 345

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

L 345: RN & structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID129508
CHEMBL ID76841
SCHEMBL ID1305530
MeSH IDM0176652

Synonyms (14)

Synonym
CHEMBL76841
L345 ,
2-methyl-2-[4-[(3,4,5-trichlorophenyl)carbamoylamino]phenoxy]propanoic acid
SCHEMBL1305530
121809-82-3
l-345
2-(4-(3,4,5-trichlorophenylureido)phenoxy)-2-methylpropionic acid
l 345
2-methyl-2-(4-((((3,4,5-trichlorophenyl)amino)carbonyl)amino)phenoxy)propanoic acid
propanoic acid, 2-methyl-2-(4-((((3,4,5-trichlorophenyl)amino)carbonyl)amino)phenoxy)-
DTXSID30153371
2-[4-(3,4,5-trichlorophenylureido)-phenoxy]-2-methylpropionic acid
2-methyl-2-(4-(3-(3,4,5-trichlorophenyl)ureido)phenoxy)propanoic acid
AKOS040752296
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (10)

Assay IDTitleYearJournalArticle
AID231976Ratio of effect of compound on affinity of hemoglobin for oxygen to that of control1989Journal of medicinal chemistry, Oct, Volume: 32, Issue:10
Synthesis and investigation of effects of 2-[4- [[(arylamino)carbonyl]amino]phenoxy]-2-methylpropionic acids on the affinity of hemoglobin for oxygen: structure-activity relationships.
AID92893Ability of 0.2 mM to reduce affinity of hemoglobin for oxygen is assessed from 50% partial pressure of oxygen in intact red cells1989Journal of medicinal chemistry, Oct, Volume: 32, Issue:10
Synthesis and investigation of effects of 2-[4- [[(arylamino)carbonyl]amino]phenoxy]-2-methylpropionic acids on the affinity of hemoglobin for oxygen: structure-activity relationships.
AID226490Oxygen pressure in mmHg at which the control hemoglobin solution (in presence of 10 mM compound) was 50% saturated with oxygen.1991Journal of medicinal chemistry, Feb, Volume: 34, Issue:2
Allosteric modifiers of hemoglobin. 1. Design, synthesis, testing, and structure-allosteric activity relationship of novel hemoglobin oxygen affinity decreasing agents.
AID92891Ability of 0.1 mM to reduce affinity of hemoglobin for oxygen is assessed from 50% partial pressure of oxygen in intact red cells1989Journal of medicinal chemistry, Oct, Volume: 32, Issue:10
Synthesis and investigation of effects of 2-[4- [[(arylamino)carbonyl]amino]phenoxy]-2-methylpropionic acids on the affinity of hemoglobin for oxygen: structure-activity relationships.
AID226491Allosteric activity evaluated as the ratio of the oxygen pressure in mmHg between hemoglobin-compound and compound-free hemoglobin (control) solution at which 50% oxygen saturation's are respectively attained.1991Journal of medicinal chemistry, Feb, Volume: 34, Issue:2
Allosteric modifiers of hemoglobin. 2. Crystallographically determined binding sites and hydrophobic binding/interaction analysis of novel hemoglobin oxygen effectors.
AID226489Oxygen pressure in mmHg at which the control hemoglobin solution (no compound) was 50% saturated with oxygen.1991Journal of medicinal chemistry, Feb, Volume: 34, Issue:2
Allosteric modifiers of hemoglobin. 1. Design, synthesis, testing, and structure-allosteric activity relationship of novel hemoglobin oxygen affinity decreasing agents.
AID221787Ability of 0.1 mM to reduce affinity of hemoglobin for oxygen is assessed from 50% partial pressure of oxygen in membrane free hemoglobin solution1989Journal of medicinal chemistry, Oct, Volume: 32, Issue:10
Synthesis and investigation of effects of 2-[4- [[(arylamino)carbonyl]amino]phenoxy]-2-methylpropionic acids on the affinity of hemoglobin for oxygen: structure-activity relationships.
AID221788Ability of 0.2 mM to reduce affinity of hemoglobin for oxygen is assessed from 50% partial pressure of oxygen in membrane free hemoglobin solution1989Journal of medicinal chemistry, Oct, Volume: 32, Issue:10
Synthesis and investigation of effects of 2-[4- [[(arylamino)carbonyl]amino]phenoxy]-2-methylpropionic acids on the affinity of hemoglobin for oxygen: structure-activity relationships.
AID221786Ability of 0.05 mM to reduce affinity of hemoglobin for oxygen is assessed from 50% partial pressure of oxygen in membrane free hemoglobin solution1989Journal of medicinal chemistry, Oct, Volume: 32, Issue:10
Synthesis and investigation of effects of 2-[4- [[(arylamino)carbonyl]amino]phenoxy]-2-methylpropionic acids on the affinity of hemoglobin for oxygen: structure-activity relationships.
AID92890Ability of 0.05 mM to reduce affinity of hemoglobin for oxygen is assessed from 50% partial pressure of oxygen in intact red cells1989Journal of medicinal chemistry, Oct, Volume: 32, Issue:10
Synthesis and investigation of effects of 2-[4- [[(arylamino)carbonyl]amino]phenoxy]-2-methylpropionic acids on the affinity of hemoglobin for oxygen: structure-activity relationships.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (6)

TimeframeStudies, This Drug (%)All Drugs %
pre-19901 (16.67)18.7374
1990's5 (83.33)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 37.34

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index37.34 (24.57)
Research Supply Index1.95 (2.92)
Research Growth Index4.99 (4.65)
Search Engine Demand Index51.20 (26.88)
Search Engine Supply Index2.24 (0.95)

This Compound (37.34)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other6 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
chlorine
chloride : A halide anion formed when chlorine picks up an electron to form an an anion.		1.9710halide anion;
monoatomic chlorine		cofactor;
Escherichia coli metabolite;
human metabolite
phytic acid
Phytic Acid: Complexing agent for removal of traces of heavy metal ions. It acts also as a hypocalcemic agent.. myo-inositol hexakisphosphate : A myo-inositol hexakisphosphate in which each hydroxy group of myo-inositol is monophosphorylated.		1.9810inositol phosphate
alanine
Alanine: A non-essential amino acid that occurs in high levels in its free state in plasma. It is produced from pyruvate by transamination. It is involved in sugar and acid metabolism, increases IMMUNITY, and provides energy for muscle tissue, BRAIN, and the CENTRAL NERVOUS SYSTEM.. alanine : An alpha-amino acid that consists of propionic acid bearing an amino substituent at position 2.		1.9810alanine zwitterion;
alanine;
L-alpha-amino acid;
proteinogenic amino acid;
pyruvate family amino acid		EC 4.3.1.15 (diaminopropionate ammonia-lyase) inhibitor;
fundamental metabolite
aspartic acid
Aspartic Acid: One of the non-essential amino acids commonly occurring in the L-form. It is found in animals and plants, especially in sugar cane and sugar beets. It may be a neurotransmitter.. aspartic acid : An alpha-amino acid that consists of succinic acid bearing a single alpha-amino substituent. L-aspartic acid : The L-enantiomer of aspartic acid.		1.9910aspartate family amino acid;
aspartic acid;
L-alpha-amino acid;
proteinogenic amino acid		Escherichia coli metabolite;
mouse metabolite;
neurotransmitter
histidine
Histidine: An essential amino acid that is required for the production of HISTAMINE.. L-histidine : The L-enantiomer of the amino acid histidine.. histidine : An alpha-amino acid that is propanoic acid bearing an amino substituent at position 2 and a 1H-imidazol-4-yl group at position 3.		1.9810amino acid zwitterion;
histidine;
L-alpha-amino acid;
polar amino acid zwitterion;
proteinogenic amino acid		algal metabolite;
Escherichia coli metabolite;
human metabolite;
micronutrient;
mouse metabolite;
nutraceutical;
Saccharomyces cerevisiae metabolite
bezafibrate
[no description available]		2.6730aromatic ether;
monocarboxylic acid amide;
monocarboxylic acid;
monochlorobenzenes		antilipemic drug;
environmental contaminant;
geroprotector;
xenobiotic
efaproxiral
efaproxiral: RN & structure given in first source; allosteric effector of hemoglobin		1.9710
rsr 4
4-(2-(4-(((3,5-dichloroanilino)carbonyl)methyl)phenoxy)-2-methylpropionic acid): allosteric effector of hemoglobin; structure given in first source		2.3820
l 35
L 35: a negative effector of hemoglobin; RN & structure given in first source		2.8940
lr 16
LR 16: structure given in first source; has potent effects on oxygen affinity of hemoglobin, on blood cholesterol and on low density lipoprotein		2.8940
heme
Heme: The color-furnishing portion of hemoglobin. It is found free in tissues and as the prosthetic group in many hemeproteins.. ferroheme : Any iron(II)--porphyrin coordination complex.. ferroheme b : Heme b in which the iron has oxidation state +2.. heme : A heme is any tetrapyrrolic chelate of iron.		1.9710
ConditionIndicatedRelationship StrengthStudiesTrials